$50.440
-0.217 (-0.43%)收盤時
GSK 資訊
GSK 事件
Hutchmed Enters Development Agreement with GSK for HMPL-A830
Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK (GSK), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a $110M upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of $1.3B, and royalties on net sales. Under the terms of the agreement, Hutchmed Limited will be responsible for the global phase I development program, which is expected to start in the second half of 2026. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.
GSK Presents Positive Phase II Data for mRNA Influenza Vaccine
GSK presented positive phase II data for its mRNA seasonal influenza vaccine candidate at the OPTIONS XIII Conference for the Control of Influenza. GSK's vaccine candidate showed higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines in younger and older adults respectively, and was generally well tolerated. Based on these results, GSK intends to start a phase III efficacy trial in September 2026. This will be the first phase III trial of an mRNA flu vaccine designed to target both haemagglutinin and neuraminidase, the primary surface antigens that cause the flu virus to bind and spread. While licensed flu vaccines primarily target HA, GSK's vaccine candidate is specifically designed to also target NA. Growing evidence suggests this could help improve protection, illness severity and transmission.
ViiV Healthcare Receives FDA Approval for Tivicay PD for Pediatric Use
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, announced that the U.S. FDA has approved Tivicay PD, for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients weighing at least 2 kg. The FDA approval follows Priority Review for this population and is supported by data from the National Institutes of Health-funded IMPAACT 2023 study and pharmacokinetic modelling incorporating additional paediatric data. These data showed that DTG, a second-generation INSTI with a higher barrier to resistance than previous generations, reached therapeutic drug levels in term neonates with a safety profile consistent with that established in older paediatric and adult populations.
GSK Receives Approval for Hibsago as Functional Cure for Chronic Hepatitis B in Japan
GSK announced that Japan's Ministry of Health, Labour and Welfare, MHLW, has approved Hibsago, an antisense oligonucleotide, ASO, as a functional cure for chronic hepatitis B, CHB, virus infection in adult patients who have received at least 6 months of prior nucleos(t)ide analogue therapy and meet pre-defined viral markers. This is the first global approval for bepirovirsen, and the first and only functional cure treatment for CHB approved in Japan. Approval in Japan was supported by results from the B-Well phase III trials showing unprecedented functional cure rates of 19% in adults with less than or equal to 3000 IU/ml HBsAg, compared to current standard of care alone which typically only achieves a 1% functional cure rate after one year of treatment.
GSK's Jemperli Receives FDA Priority Review
GSK announced the US Food and Drug Administration, FDA, has accepted for priority review a supplemental Biologics License Application, sBLA, for Jemperli for patients with previously untreated stage II and III mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer. The FDA has assigned a PDUFA action date of February 2027. The application is also eligible for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision. The application is based on positive data from the registrational phase II, single-arm AZUR-1 trial, which met its primary objective by demonstrating a meaningful and sustained clinical complete response rate for 12 months with no detectable signs of cancer for at least one year.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。